The role of dopamine in the brain - Lessons learned from Parkinson's disease
暂无分享,去创建一个
Hartwig R. Siebner | Stéphane Lehéricy | David Meder | Damian Marc Herz | James Benedict Rowe | S. Lehéricy | J. Rowe | H. Siebner | D. Herz | David Meder
[1] Peter S. Jones,et al. Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures , 2016, Human brain mapping.
[2] M. Gluck,et al. Dopaminergic Drugs Modulate Learning Rates and Perseveration in Parkinson's Patients in a Dynamic Foraging Task , 2009, The Journal of Neuroscience.
[3] Marios Politis,et al. Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. , 2013, Brain : a journal of neurology.
[4] Ji Hyun Ko,et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study , 2012, Neurobiology of Disease.
[5] B. Forstmann,et al. Frontosubthalamic Circuits for Control of Action and Cognition , 2016, The Journal of Neuroscience.
[6] K. Chaudhuri,et al. Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.
[7] T. Robbins,et al. Chemical neuromodulation of frontal-executive functions in humans and other animals , 2000, Experimental Brain Research.
[8] M. Muenter,et al. Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.
[9] K. Jellinger. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? , 1999, Journal of neural transmission. Supplementum.
[10] Timothy E. J. Behrens,et al. Learning the value of information in an uncertain world , 2007, Nature Neuroscience.
[11] Antonio Cerasa,et al. The motor inhibition system in Parkinson's disease with levodopa‐induced dyskinesias , 2015, Movement disorders : official journal of the Movement Disorder Society.
[12] Adam R. Aron,et al. Is executive control used to compensate for involuntary movements in levodopa‐induced dyskinesia? , 2012, Movement disorders : official journal of the Movement Disorder Society.
[13] P. Dayan,et al. Dopamine Increases a Value-Independent Gambling Propensity , 2016, Neuropsychopharmacology.
[14] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[15] Hartwig R. Siebner,et al. The motor system and its disorders , 2012, NeuroImage.
[16] Antonio Cerasa,et al. A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias. , 2015, Brain : a journal of neurology.
[17] S. Eickhoff,et al. Functional neuroimaging of motor control in parkinson's disease: A meta‐analysis , 2014, Human brain mapping.
[18] L. Timmermann,et al. A systematic review on the applications of resting-state fMRI in Parkinson's disease: Does dopamine replacement therapy play a role? , 2015, Cortex.
[19] M. Hallett,et al. Dopamine agonists and risk: impulse control disorders in Parkinson's disease. , 2011, Brain : a journal of neurology.
[20] W. Schultz. Reward prediction error , 2017, Current Biology.
[21] Thomas Foltynie,et al. Early nucleus basalis of Meynert degeneration predicts cognitive decline in Parkinson's disease. , 2018, Brain : a journal of neurology.
[22] S. Haber. The primate basal ganglia: parallel and integrative networks , 2003, Journal of Chemical Neuroanatomy.
[23] R. Cilia,et al. Impulse control disorders in Parkinson’s disease: seeking a roadmap toward a better understanding , 2011, Brain Structure and Function.
[24] Roger A. Barker,et al. Cognitive Impairment in Parkinson's Disease: The Dual Syndrome Hypothesis , 2012, Neurodegenerative Diseases.
[25] A. Strafella,et al. Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease? , 2009, Neuropsychopharmacology.
[26] W Birkmayer,et al. The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961. , 2001, Wiener klinische Wochenschrift.
[27] M. Pessiglione,et al. A Selective Role for Dopamine in Learning to Maximize Reward But Not to Minimize Effort: Evidence from Patients with Parkinson's Disease , 2017, The Journal of Neuroscience.
[28] Karl J. Friston,et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. , 1999, Brain : a journal of neurology.
[29] Matthew F. S. Rushworth,et al. Weighing up the benefits of work: Behavioral and neural analyses of effort-related decision making , 2006, Neural Networks.
[30] C. Halldin,et al. Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy , 2008, Neurology.
[31] K. Ray Chaudhuri,et al. Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.
[32] D. Eckstein,et al. Parkinson's disease and dopaminergic therapy—differential effects on movement, reward and cognition , 2008, Brain : a journal of neurology.
[33] B. Forstmann,et al. Neurocognitive mechanisms of action control: resisting the call of the Sirens. , 2011, Wiley interdisciplinary reviews. Cognitive science.
[34] S. Kish,et al. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.
[35] Yi Li,et al. Dopamine Is Required for the Neural Representation and Control of Movement Vigor , 2015, Cell.
[36] M. Husain,et al. Distinct effects of apathy and dopamine on effort-based decision-making in Parkinson’s disease , 2018, Brain : a journal of neurology.
[37] P. Calabresi,et al. Abnormal Synaptic Plasticity in the Striatum of Mice Lacking Dopamine D2 Receptors , 1997, The Journal of Neuroscience.
[38] G C Cotzias,et al. L-dopa in parkinson's syndrome. , 1969, The New England journal of medicine.
[39] H. Braak,et al. A timeline for Parkinson's disease. , 2010, Parkinsonism & related disorders.
[40] J. Massano,et al. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. , 2012, Cold Spring Harbor perspectives in medicine.
[41] Alfonso Barrós-Loscertales,et al. Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of pre-learned sequential movements , 2007, Brain Research.
[42] M. Gluck,et al. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. , 2009, Brain : a journal of neurology.
[43] Marianna Amboni,et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa , 2014, Brain : a journal of neurology.
[44] Robert A. Hauser,et al. Levodopa: Past, Present, and Future , 2008, European Neurology.
[45] Michael C. Anderson,et al. Selection and stopping in voluntary action: A meta-analysis and combined fMRI study , 2014, NeuroImage.
[46] Antonio P. Strafella,et al. Top-down Control of Dyskinesias in PD Using Brain Stimulation , 2014, Brain Stimulation.
[47] Chris C. Tang,et al. Abnormalities in Metabolic Network Activity Precede the Onset of Motor Symptoms in Parkinson's Disease , 2010, The Journal of Neuroscience.
[48] Roshan Cools,et al. Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective , 2014, Movement disorders : official journal of the Movement Disorder Society.
[49] P. Smittenaar,et al. Decomposing effects of dopaminergic medication in Parkinson’s disease on probabilistic action selection – learning or performance? , 2012, The European journal of neuroscience.
[50] Ji Hyun Ko,et al. Metabolic resting-state brain networks in health and disease , 2015, Proceedings of the National Academy of Sciences.
[51] Scott T Grafton,et al. The functional anatomy of parkinsonian bradykinesia , 2003, NeuroImage.
[52] M. Husain,et al. Dopamine enhances willingness to exert effort for reward in Parkinson's disease , 2015, Cortex.
[53] Luca Passamonti,et al. Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease , 2016, Neuropsychopharmacology.
[54] U Sabatini,et al. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. , 1998, Brain : a journal of neurology.
[55] Roger A. Barker,et al. Perseveration and Choice in Parkinson's Disease: The Impact of Progressive Frontostriatal Dysfunction on Action Decisions , 2012, Cerebral cortex.
[56] Caroline H. Williams-Gray,et al. The Genetic Basis of Cognitive Impairment and Dementia in Parkinson’s Disease , 2016, Front. Psychiatry.
[57] G. Berns. Functional neuroimaging. , 1999, Life sciences.
[58] John G Nutt,et al. Pharmacokinetics and pharmacodynamics of levodopa , 2008, Movement disorders : official journal of the Movement Disorder Society.
[59] D. Aarsland,et al. A systematic review of prevalence studies of dementia in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.
[60] H. Forssberg,et al. Coordination of Manipulative Forces in Parkinson's Disease , 1997, Experimental Neurology.
[61] Anne G E Collins,et al. Opponent actor learning (OpAL): modeling interactive effects of striatal dopamine on reinforcement learning and choice incentive. , 2014, Psychological review.
[62] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[63] Robert C. Wilson,et al. An Approximately Bayesian Delta-Rule Model Explains the Dynamics of Belief Updating in a Changing Environment , 2010, The Journal of Neuroscience.
[64] Jakob Kisbye Dreyer,et al. How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum , 2016, Movement disorders : official journal of the Movement Disorder Society.
[65] James B. Rowe,et al. Multiple Modes of Impulsivity in Parkinson's Disease , 2014, PloS one.
[66] M. Hallett,et al. A physiological mechanism of bradykinesia. , 1980, Brain : a journal of neurology.
[67] G. Steg,et al. THE EFFECT OF L-3, 4-DIHYDROXYPHENYLALANINE AND DL-5-HYDROXYTRYPTOPHAN ON RIGIDITY AND TREMOR INDUCED BY RESERPINE, CHLORPROMAZINE AND PHENOXYBENZAMINE. , 1964, Life sciences.
[68] Michael J Frank,et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update , 2017, The Lancet Neurology.
[69] D J Brooks,et al. Neuroimaging of dyskinesia. , 2000, Annals of neurology.
[70] Jan Booij,et al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[71] K. Jellinger,et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.
[72] R. Morris,et al. Dopamine and Memory: Modulation of the Persistence of Memory for Novel Hippocampal NMDA Receptor-Dependent Paired Associates , 2010, The Journal of Neuroscience.
[73] Viviana Versace,et al. Low frequency rTMS of the SMA transiently ameliorates peak-dose LID in Parkinson’s disease , 2006, Clinical Neurophysiology.
[74] M. Desmurget,et al. A Common Optimization Principle for Motor Execution in Healthy Subjects and Parkinsonian Patients , 2013, The Journal of Neuroscience.
[75] Fabrizio Esposito,et al. Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa. , 2013, Brain : a journal of neurology.
[76] Edna Ty,et al. Dyskinetic Parkinson’s disease patients demonstrate motor abnormalities off medication , 2011, Experimental Brain Research.
[77] Roger A. Barker,et al. Improving Response Inhibition in Parkinson’s Disease with Atomoxetine , 2015, Biological Psychiatry.
[78] Jon E. Grant,et al. Impulse Control Disorders: Updated Review of Clinical Characteristics and Pharmacological Management , 2011, Front. Psychiatry.
[79] Roger A. Barker,et al. Atomoxetine restores the response inhibition network in Parkinson’s disease , 2016, Brain : a journal of neurology.
[80] C. Büchel,et al. Pharmacologically modulated fMRI--cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients. , 2003, Brain : a journal of neurology.
[81] D. Aarsland,et al. A systematic review of prevalence studies of depression in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[82] J. Daunizeau,et al. Computational Dissection of Dopamine Motor and Motivational Functions in Humans , 2016, The Journal of Neuroscience.
[83] D. Lulé,et al. Levodopa-induced striatal activation in Parkinson's disease: a functional MRI study. , 2009, Parkinsonism & related disorders.
[84] M. Hallett,et al. Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors , 2010, Neuron.
[85] C Caltagirone,et al. rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease , 2005, Neurology.
[86] Daniel Weintraub,et al. Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[87] V Kaasinen,et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. , 2001, Brain : a journal of neurology.
[88] A. Strafella,et al. Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease? , 2009, Neuropsychopharmacology.
[89] Roshan Cools,et al. Greater striatal responses to medication in Parkinson׳s disease are associated with better task-switching but worse reward performance , 2014, Neuropsychologia.
[90] Kristoffer Hougaard Madsen,et al. Simultaneous representation of a spectrum of dynamically changing value estimates during decision making , 2017 .
[91] Alexander Münchau,et al. Attenuated neural response to gamble outcomes in drug-naive patients with Parkinson's disease. , 2013, Brain : a journal of neurology.
[92] R. Cools. Dopaminergic modulation of cognitive function-implications for l-DOPA treatment in Parkinson's disease , 2006, Neuroscience & Biobehavioral Reviews.
[93] Hartwig R. Siebner,et al. Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans , 2015, Brain : a journal of neurology.
[94] P. Goldman-Rakic,et al. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys , 1994, Psychopharmacology.
[95] Sylvain Houle,et al. [11C]‐(+)‐PHNO PET imaging of dopamine D2/3 receptors in Parkinson's disease with impulse control disorders , 2015, Movement disorders : official journal of the Movement Disorder Society.
[96] A. Lang,et al. Parkinson's disease , 2015, The Lancet.
[97] T. Robbins,et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. , 2001, Cerebral cortex.
[98] O. Hornykiewicz,et al. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.
[99] Xiaowei Zhuang,et al. Incorporating spatial constraint in co-activation pattern analysis to explore the dynamics of resting-state networks: An application to Parkinson's disease , 2018, NeuroImage.
[100] E. Montgomery. Pharmacokinetics and pharmacodynamics of levodopa , 1992, Neurology.
[101] Ulrik R Beierholm,et al. Dopamine Modulates Reward-Related Vigor , 2013, Neuropsychopharmacology.
[102] B. Averbeck,et al. Uncertainty about mapping future actions into rewards may underlie performance on multiple measures of impulsivity in behavioral addiction: evidence from Parkinson's disease. , 2013, Behavioral neuroscience.
[103] R. Barker,et al. The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease , 2010, Neurobiology of Aging.
[104] M. Cenci,et al. Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia , 2006, Journal of neurochemistry.
[105] Ruth Sander. Impulse control disorders and levodopa-induced dyskinesias , 2017 .
[106] Marjan Jahanshahi,et al. Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson’s disease , 2011, Experimental Brain Research.
[107] Roshan Cools,et al. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss , 2012, NeuroImage.
[108] P. Strick,et al. Imaging the premotor areas , 2001, Current Opinion in Neurobiology.
[109] J. Krakauer,et al. Why Don't We Move Faster? Parkinson's Disease, Movement Vigor, and Implicit Motivation , 2007, The Journal of Neuroscience.
[110] F. Vingerhoets,et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? , 1997, Annals of neurology.
[111] Rachel Tomer,et al. Effects of asymmetric dopamine depletion on sensitivity to rewarding and aversive stimuli in Parkinson's disease , 2013, Neuropsychologia.
[112] Hartwig R. Siebner,et al. The acute brain response to levodopa heralds dyskinesias in Parkinson disease , 2014, Annals of neurology.
[113] R. Barker,et al. Parkinson's disease and healthy aging: Independent and interacting effects on action selection , 2010, Human brain mapping.
[114] Kristoffer Hougaard Madsen,et al. Motivational Tuning of Fronto-Subthalamic Connectivity Facilitates Control of Action Impulses , 2014, The Journal of Neuroscience.
[115] David J. Brooks,et al. Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study , 2014, Brain : a journal of neurology.
[116] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[117] C. Kennard,et al. Functional role of the supplementary and pre-supplementary motor areas , 2008, Nature Reviews Neuroscience.
[118] M. Pessiglione,et al. Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes , 2009, Proceedings of the National Academy of Sciences.
[119] S. Houle,et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. , 2009, Brain : a journal of neurology.
[120] J. Krakauer,et al. The basal ganglia: from motor commands to the control of vigor , 2016, Current Opinion in Neurobiology.
[121] A Verniory,et al. Serum renin levels and postnephrectomy blood pressure. , 1969, The New England journal of medicine.
[122] Oury Monchi,et al. The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward , 2017, Movement disorders : official journal of the Movement Disorder Society.
[123] M. A. MacIver,et al. Neuroscience Needs Behavior: Correcting a Reductionist Bias , 2017, Neuron.
[124] Erin Kendall Braun,et al. Mind matters: Placebo enhances reward learning in Parkinson’s disease , 2014, Nature Neuroscience.
[125] Kalen J. Petersen,et al. Mesocorticolimbic hemodynamic response in Parkinson's disease patients with compulsive behaviors , 2017, Movement disorders : official journal of the Movement Disorder Society.
[126] A. Lang,et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. , 2010, Archives of neurology.
[127] Antonio Cerasa,et al. Increased prefrontal volume in PD with levodopa‐induced dyskinesias: A voxel‐based morphometry study , 2011, Movement disorders : official journal of the Movement Disorder Society.
[128] V. Menon,et al. Compensatory neural mechanisms in cognitively unimpaired Parkinson disease , 2016, Annals of neurology.
[129] Stephanie L. Alberico,et al. The Vulnerable Ventral Tegmental Area in Parkinson's Disease. , 2015, Basal ganglia.
[130] D. Vaillancourt,et al. Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease , 2010, Human brain mapping.
[131] D. Eidelberg. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach , 2009, Trends in Neurosciences.
[132] Valerie Voon,et al. Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[133] R. Bogacz,et al. Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making , 2012, Brain : a journal of neurology.
[134] T. Robbins,et al. L-DOPA Disrupts Activity in the Nucleus Accumbens during Reversal Learning in Parkinson's Disease , 2007, Neuropsychopharmacology.
[135] Dagmar Verbaan,et al. Cognitive impairment in Parkinson's , 2007 .
[136] M Schulzer,et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias , 2009, Neurology.
[137] M. Hallett,et al. Pathophysiology of bradykinesia in Parkinson's disease. , 2001, Brain : a journal of neurology.
[138] R. Bogacz,et al. Effects of dopamine on reinforcement learning and consolidation in Parkinson’s disease , 2017, eLife.
[139] Antonio Cerasa,et al. Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease , 2015, Front. Neurol..
[140] R. Cools,et al. Reward learning deficits in Parkinson’s disease depend on depression , 2016, bioRxiv.
[141] George I. Christopoulos,et al. Neural Correlates of Value, Risk, and Risk Aversion Contributing to Decision Making under Risk , 2009, The Journal of Neuroscience.
[142] W Birkmayer,et al. The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. , 1998, Parkinsonism & related disorders.
[143] John C Rothwell,et al. Can levodopa-induced dyskinesias go beyond the motor circuit? , 2015, Brain : a journal of neurology.
[144] Karl J. Friston,et al. The Trouble with Cognitive Subtraction , 1996, NeuroImage.
[145] Bradley L. Schlaggar,et al. The Fallacy of Univariate Solutions to Complex Systems Problems , 2016, Front. Neurosci..
[146] Hartwig R. Siebner,et al. Resting‐state connectivity predicts levodopa‐induced dyskinesias in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.
[147] Raymond J. Dolan,et al. Value encoding in the globus pallidus: fMRI reveals an interaction effect between reward and dopamine drive , 2017, NeuroImage.
[148] Timothy Edward John Behrens,et al. Changes in connectivity profiles define functionally distinct regions in human medial frontal cortex. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[149] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[150] Sylvain Houle,et al. Abnormal intrinsic brain functional network dynamics in Parkinson’s disease , 2017, Brain : a journal of neurology.
[151] M. Frank,et al. Computational psychiatry as a bridge from neuroscience to clinical applications , 2016, Nature Neuroscience.
[152] Elias Aboujaoude,et al. Impulse Control Disorders: Impulse Control Disorders , 2010 .
[153] Michael J. Frank,et al. By Carrot or by Stick: Cognitive Reinforcement Learning in Parkinsonism , 2004, Science.
[154] Brian A. Nosek,et al. Power failure: why small sample size undermines the reliability of neuroscience , 2013, Nature Reviews Neuroscience.
[155] Chonho Lee,et al. Excessive Sensitivity to Uncertain Visual Input in L-DOPA-Induced Dyskinesias in Parkinson’s Disease: Further Implications for Cerebellar Involvement , 2013, Front. Neurol..
[156] Penny A. MacDonald,et al. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI. , 2011, Brain : a journal of neurology.
[157] David Eidelberg,et al. Parkinson's disease‐related network topographies characterized with resting state functional MRI , 2017, Human brain mapping.
[158] P. Dayan,et al. Tonic dopamine: opportunity costs and the control of response vigor , 2007, Psychopharmacology.
[159] W. Schultz. Neuronal Reward and Decision Signals: From Theories to Data. , 2015, Physiological reviews.
[160] P. Strick,et al. Frontal lobe inputs to primate motor cortex: evidence for four somatotopically organized ‘premotor’ areas , 1979, Brain Research.
[161] Roger A. Barker,et al. Genetic Neuroimaging Studies of Basal Ganglia Disorders , 2016 .
[162] P. Dayan,et al. Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease. , 2012 .
[163] Marios Politis,et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. , 2011, Brain : a journal of neurology.
[164] J. H. Krystal,et al. 208. Increased striatal dopamine release in drug free schizophrenic subjects , 1996, Biological Psychiatry.
[165] Antonio Cerasa,et al. Prefrontal alterations in Parkinson's disease with levodopa‐induced dyskinesia during fMRI motor task , 2012, Movement disorders : official journal of the Movement Disorder Society.
[166] G. Deuschl,et al. Force overflow and levodopa-induced dyskinesias in Parkinson's disease. , 2002, Brain : a journal of neurology.
[167] A. Strafella,et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling , 2010, Neurobiology of Disease.
[168] Thomas Foltynie,et al. Parkinson’s disease dementia: a neural networks perspective , 2015, Brain : a journal of neurology.
[169] A M Owen,et al. Prefrontal dopamine levels determine the balance between cognitive stability and flexibility. , 2013, Cerebral cortex.